GB9619074D0 - Composition - Google Patents

Composition

Info

Publication number: GB9619074D0
Authority: GB; United Kingdom
Prior art keywords: composition
Prior art date: 1996-09-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

GBGB9619074.9A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Ltd

Original Assignee

SmithKline Beecham Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1996-09-12

Publication date

1996-10-23

1996-09-12 Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd

1996-09-12 Priority to GBGB9619074.9A priority Critical patent/GB9619074D0/en

1996-10-23 Publication of GB9619074D0 publication Critical patent/GB9619074D0/en

1997-09-08 Priority to KR1019997002030A priority patent/KR20000036039A/en

1997-09-08 Priority to PL97332074A priority patent/PL332074A1/en

1997-09-08 Priority to IL12878197A priority patent/IL128781A0/en

1997-09-08 Priority to JP10513352A priority patent/JP2001500150A/en

1997-09-08 Priority to PCT/GB1997/002418 priority patent/WO1998010762A2/en

1997-09-08 Priority to CA002265661A priority patent/CA2265661A1/en

1997-09-08 Priority to CZ99832A priority patent/CZ83299A3/en

1997-09-08 Priority to TR1999/00505T priority patent/TR199900505T2/xx

1997-09-08 Priority to EP97939064A priority patent/EP0929301A2/en

1997-09-08 Priority to CN97199411A priority patent/CN1235544A/en

1997-09-08 Priority to HU9904401A priority patent/HUP9904401A3/en

1997-09-08 Priority to BR9711734A priority patent/BR9711734A/en

1997-09-08 Priority to AU41288/97A priority patent/AU724086B2/en

1997-09-08 Priority to NZ334268A priority patent/NZ334268A/en

1997-09-09 Priority to CO97052280A priority patent/CO5031291A1/en

1997-09-10 Priority to PE1997000805A priority patent/PE2499A1/en

1997-09-10 Priority to IDP973137A priority patent/ID19589A/en

1997-09-10 Priority to ARP970104130A priority patent/AR008176A1/en

1997-09-10 Priority to ZA978133A priority patent/ZA978133B/en

1997-09-10 Priority to MA24792A priority patent/MA24359A1/en

1999-03-11 Priority to NO991194A priority patent/NO991194L/en

2001-01-12 Priority to US09/759,576 priority patent/US20010003588A1/en

2001-09-19 Priority to US09/956,617 priority patent/US6468560B2/en

2002-08-28 Priority to US10/229,645 priority patent/US20030157169A1/en

2003-01-23 Priority to CN03102977A priority patent/CN1446535A/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

GBGB9619074.9A 1996-09-12 1996-09-12 Composition Pending GB9619074D0 (en)

Priority Applications (26)

Application Number	Priority Date	Filing Date	Title
GBGB9619074.9A GB9619074D0 (en)	1996-09-12	1996-09-12	Composition
TR1999/00505T TR199900505T2 (en)	1996-09-12	1997-09-08
BR9711734A BR9711734A (en)	1996-09-12	1997-09-08	Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride
NZ334268A NZ334268A (en)	1996-09-12	1997-09-08	Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride
IL12878197A IL128781A0 (en)	1996-09-12	1997-09-08	Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
JP10513352A JP2001500150A (en)	1996-09-12	1997-09-08	Controlled release dosage form of [R- (Z)]-α- (methoxyimino) -α- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride
PCT/GB1997/002418 WO1998010762A2 (en)	1996-09-12	1997-09-08	Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
CA002265661A CA2265661A1 (en)	1996-09-12	1997-09-08	Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl)acetonitrile monohydrochloride
CZ99832A CZ83299A3 (en)	1996-09-12	1997-09-08	Controlled release controlled release form of [R- (Z)] - alpha- (methoxyimino) -alpha- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride
PL97332074A PL332074A1 (en)	1996-09-12	1997-09-08	Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride
EP97939064A EP0929301A2 (en)	1996-09-12	1997-09-08	Controlled release dosage form of r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2]oct-3-yl)acetonitrile monohydrochloride
CN97199411A CN1235544A (en)	1996-09-12	1997-09-08	Hydrochloric acid [R-(Z)]-α-methoxyimino-α-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile controlled release dosage form
HU9904401A HUP9904401A3 (en)	1996-09-12	1997-09-08	Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
KR1019997002030A KR20000036039A (en)	1996-09-12	1997-09-08	Controlled Release Dosage Form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile Monohydrochloride
AU41288/97A AU724086B2 (en)	1996-09-12	1997-09-08	Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
CO97052280A CO5031291A1 (en)	1996-09-12	1997-09-09	PHARMACEUTICAL COMPOSITION
MA24792A MA24359A1 (en)	1996-09-12	1997-09-10	PROCESS FOR THE NEW FORMULATION OF MONOCHLORHYDRATE OF [R- (Z) -alpha- (METHOXYIMINO-ALPHA- (1-AZABICYCLO [2-2-2] OCT-3-YL) -ACETONITRIYLE?
PE1997000805A PE2499A1 (en)	1996-09-12	1997-09-10	COATING COMPOSITIONS THAT CONTROL RELEASE
IDP973137A ID19589A (en)	1996-09-12	1997-09-10	COMPOSITION
ARP970104130A AR008176A1 (en)	1996-09-12	1997-09-10	ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
ZA978133A ZA978133B (en)	1996-09-12	1997-09-10	Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride
NO991194A NO991194L (en)	1996-09-12	1999-03-11	Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride
US09/759,576 US20010003588A1 (en)	1996-09-12	2001-01-12	Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US09/956,617 US6468560B2 (en)	1996-09-12	2001-09-19	Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
US10/229,645 US20030157169A1 (en)	1996-09-12	2002-08-28	Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
CN03102977A CN1446535A (en)	1996-09-12	2003-01-23	Chlorhydric [R(2)-alpha-methoxyimindogen-alpha-(1-dicycloaza [2.2.2] caryl-3-group) acetonitrile control-released dosage form

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9619074.9A GB9619074D0 (en)	1996-09-12	1996-09-12	Composition

Publications (1)

Publication Number	Publication Date
GB9619074D0 true GB9619074D0 (en)	1996-10-23

Family

ID=10799833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB9619074.9A Pending GB9619074D0 (en)	1996-09-12	1996-09-12	Composition

Country Status (22)

Country	Link
EP (1)	EP0929301A2 (en)
JP (1)	JP2001500150A (en)
KR (1)	KR20000036039A (en)
CN (2)	CN1235544A (en)
AR (1)	AR008176A1 (en)
AU (1)	AU724086B2 (en)
BR (1)	BR9711734A (en)
CA (1)	CA2265661A1 (en)
CO (1)	CO5031291A1 (en)
CZ (1)	CZ83299A3 (en)
GB (1)	GB9619074D0 (en)
HU (1)	HUP9904401A3 (en)
ID (1)	ID19589A (en)
IL (1)	IL128781A0 (en)
MA (1)	MA24359A1 (en)
NO (1)	NO991194L (en)
NZ (1)	NZ334268A (en)
PE (1)	PE2499A1 (en)
PL (1)	PL332074A1 (en)
TR (1)	TR199900505T2 (en)
WO (1)	WO1998010762A2 (en)
ZA (1)	ZA978133B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2775597B1 (en) *	1998-03-04	2001-04-20	Gattefosse Ets Sa	ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
PL342600A1 (en)	1998-03-11	2001-06-18	Smithkline Beecham Plc	Composition
DE19918325A1 (en) *	1999-04-22	2000-10-26	Euro Celtique Sa	Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) *	1999-07-26	2003-06-20	Ethypharm Lab Prod Ethiques	LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) *	2000-12-06	2004-05-11	Wyeth	Fast dissolving tablet
PE20040134A1 (en)	2002-07-25	2004-03-06	Pharmacia Corp	PRAMIPEXOL ONCE-A-DAY DOSAGE FORM
JP4808612B2 (en)	2003-04-25	2011-11-02	田辺三菱製薬株式会社	Composition for oral administration containing alkylenedioxybenzene derivative
US20070009596A1 (en) *	2003-05-14	2007-01-11	Bruschi Stefano D L	Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) *	2003-06-23	2005-06-30	Neurochem (International) Limited	Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) *	2004-03-24	2005-10-06	Ohara Yakuhin Kogyo Kk	Method for producing solid preparation
EA200700388A1 (en) *	2004-08-13	2007-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	THE COMPOSITION OF PELLETS OF THE PROLONGED SURVENT, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, THE WAY OF ITS MANUFACTURE AND ITS APPLICATION
PT1781260E (en)	2004-08-13	2010-12-20	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1970056A1 (en) *	2007-03-15	2008-09-17	Polichem S.A.	Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en)	2014-09-12	2015-09-15	Alkermes Pharma Ireland Limited	Abuse resistant pharmaceutical compositions
EP3955910A4 (en) *	2019-04-19	2023-01-25	Hoffman Technologies LLC.	EXTENDED RELEASE FORMULATIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE269330T1 (en) *	1989-04-13	2004-07-15	Beecham Group Plc	CHEMICAL COMPOUNDS
GB9409718D0 (en) *	1994-05-14	1994-07-06	Smithkline Beecham Plc	Novel compounds
GB9421472D0 (en) *	1994-10-25	1994-12-07	Smithkline Beecham Plc	Novel methods
AR004178A1 (en) *	1995-07-29	1998-11-04	Smithkline Beecham Plc	PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
1997
- 1997-09-08 CN CN97199411A patent/CN1235544A/en active Pending
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/en not_active Ceased
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 BR BR9711734A patent/BR9711734A/en unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/en active Pending
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Ceased
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/en unknown
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/en unknown
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 PL PL97332074A patent/PL332074A1/en unknown
- 1997-09-08 NZ NZ334268A patent/NZ334268A/en unknown
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 IL IL12878197A patent/IL128781A0/en unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/en unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/en unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/en not_active Application Discontinuation
- 1997-09-10 ZA ZA978133A patent/ZA978133B/en unknown
- 1997-09-10 MA MA24792A patent/MA24359A1/en unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/en not_active Application Discontinuation
1999
- 1999-03-11 NO NO991194A patent/NO991194L/en unknown
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/en active Pending

Also Published As

Publication number	Publication date
EP0929301A2 (en)	1999-07-21
KR20000036039A (en)	2000-06-26
NO991194D0 (en)	1999-03-11
BR9711734A (en)	1999-08-24
AR008176A1 (en)	1999-12-09
CN1446535A (en)	2003-10-08
WO1998010762A3 (en)	1998-06-04
PL332074A1 (en)	1999-08-30
MA24359A1 (en)	1998-07-01
PE2499A1 (en)	1999-03-24
CN1235544A (en)	1999-11-17
NZ334268A (en)	2000-10-27
CA2265661A1 (en)	1998-03-19
HUP9904401A3 (en)	2001-03-28
AU4128897A (en)	1998-04-02
HUP9904401A2 (en)	2000-06-28
IL128781A0 (en)	2000-01-31
ID19589A (en)	1998-07-23
AU724086B2 (en)	2000-09-14
ZA978133B (en)	1999-04-12
CZ83299A3 (en)	1999-08-11
JP2001500150A (en)	2001-01-09
TR199900505T2 (en)	1999-06-21
NO991194L (en)	1999-03-11
WO1998010762A2 (en)	1998-03-19
CO5031291A1 (en)	2001-04-27

Publication	Publication Date	Title
GB9612067D0 (en)	1996-08-14	Composition
GB9624874D0 (en)	1997-01-15	Composition
GB9600426D0 (en)	1996-03-13	Compositions
GB9601398D0 (en)	1996-03-27	Composition
GB9612595D0 (en)	1996-08-21	Composition
GB9605247D0 (en)	1996-05-15	Composition
EP0884044A4 (en)	2001-08-29	Hairtreatment composition
GB9619074D0 (en)	1996-10-23	Composition
GB9600604D0 (en)	1996-03-13	Composition
GB9602266D0 (en)	1996-04-03	Composition
GB9623562D0 (en)	1997-01-08	Sachet-packaged compositions
GB9620504D0 (en)	1996-11-20	Compositions
GB9610966D0 (en)	1996-07-31	Composition
ZA97698B (en)	1998-07-28	Composition
PL330421A1 (en)	1999-05-10	Antiprespirant composition
GB9620503D0 (en)	1996-11-20	Compositions
GB9604585D0 (en)	1996-05-01	Composition
GB9611365D0 (en)	1996-08-07	Compositions
GB9600545D0 (en)	1996-03-13	Compositions
GB9608390D0 (en)	1996-06-26	Composition
GB9613644D0 (en)	1996-08-28	Composition
GB9625479D0 (en)	1997-01-22	Composition
GB9625040D0 (en)	1997-01-22	Composition
GB9624211D0 (en)	1997-01-08	Composition
GB9604945D0 (en)	1996-05-08	Composition